# Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

> **NCT05309187** · PHASE1 · COMPLETED · sponsor: **Immune-Onc Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** IO-202
- **BIOLOGICAL:** IO-202 + pembrolizumab combination therapy
- **BIOLOGICAL:** RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types

## Key facts

- **NCT ID:** NCT05309187
- **Lead sponsor:** Immune-Onc Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-05-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05309187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05309187, "Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05309187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*